Two weeks after announcing the resignation of its CEO, Metamark Genetics Inc. in Cambridge has filed for the receipt of $9 million out of a $13 million Series B round of financing which it plans to use for final clinical validation of two prostate cancer prognostic tests.

In an announcement on the company’s website on Nov. 5, Metamark did not specify any of the 10 investors involved in the round, but said that they are both current and new private investors. Related persons listed on the filing are all existing executives and directors.

The same announcement named Michael Kauffman, co-founder of Karyopharm Therapeutics, to the company’s board of directors and to serve as interim executive director until a president and CEO is appointed to replace Mark Straley, who was said to have resigned to pursue other opportunities. Straley, former worldwide president of Johnson & Johnson’s Diagnostics division who also worked at Bayer Healthcare and Abbott Laboratories, was named CEO two years ago.

Founded in 2007, the company is developing two prognostic tests. The first it intends to test a patient’s prostate cancer biopsy tissue to help determine if they have a slow-growing or aggressive form of prostate cancer, and the second is designed to predict the course of the disease in the long-term.

The company did not respond to a request for comment as of deadline.

Related links:

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.